JRE #2461 - Robert F. Kennedy Jr. · Aired Feb 27, 2026
Claim summary · not a verbatim quotation
Chronic disease in American children has skyrocketed from 12% in 1986 to 54% today.
The finding
What the evidence shows
While chronic disease rates in children have genuinely increased, Kennedy's specific figures (12% in 1986 → 54% today) are disputed. The 54% figure appears to derive from a 2011 JAMA Pediatrics study measuring any chronic condition broadly, including mild conditions like skin allergies. More targeted analyses show lower rates. The trend of increasing chronic disease is real, but the specific percentage is likely inflated by expansive definitions of 'chronic condition.' Causally linking this solely to vaccines is not supported by evidence.
Read the supporting source · jamanetwork.com ↗Quick answer & review status
Quick answer
Is it true that Chronic disease in American children has skyrocketed from 12% in 1986 to 54% today?
Partly. The claim stretches what the evidence shows. While chronic disease rates in children have genuinely increased, Kennedy's specific figures (12% in 1986 → 54% today) are disputed. The 54% figure appears to derive from a 2011 JAMA Pediatrics study measuring any chronic condition broadly, including mild conditions like skin allergies. It was said on JRE #2461 - Robert F. Kennedy Jr., aired Feb 27, 2026, at 3:08:15. We haven't independently confirmed who said it. The supporting source is jamanetwork.com, linked below.
The context belongs here.
No separately verified on-air correction is recorded for this check. That is not a claim that nobody corrected it.
- Attribution
- Not independently confirmed in this record
- Editorial context review
- Not recorded; generated finding
- Coverage
- One selected claim from the episode
Revisions to this check
No dated revision is recorded here. Older checks may predate this log.
Challenge this finding or add context →Keep the evidence coming.
Follow new checks in your RSS reader, or catch up with the weekly briefing on the site.
Email signup is currently unavailable.
Prefer to catch up here? Read the weekly briefing.